Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22

Cited by papers we hold 9

• Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments · 2023
  Corrected
• Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating · 2023
  No notice
• CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy · 2022
  No notice
• Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma · 2021
  No notice
• CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial · 2021
  No notice
• CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression · 2020
  No notice
• Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia · 2020
  Corrected
• Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies · 2019
  No notice
• Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.